Consultant for Translational R&D

  • Efficacious drugs in therapeutic areas with high unmet medical need
  • Safety margin resulting in convincing therapeutic window and allowing individual dosing
  • Precision drugs targeting the right patient population and reducing failure rate
  • Successful translational research strategy based on human drug target validation
  • Decisive data enabling go/no-go decisions
  • Risk mitigation strategy
  • Identifies key experiments mitigating the risk of clinical failure
  • Integrates clinical and non-clinical requirements to speed up drug development
  • Anticipates and considers regulatory needs for successful milestone coverage
  • Efficacious drugs in therapeutic areas with high unmet medical need
  • Safety margin resulting in convincing therapeutic window and allowing individual dosing
  • Precision drugs targeting the right patient population and reducing failure rate
  • Successful translational research strategy based on human drug target validation
  • Decisive data enabling go/no-go decisions
  • Risk mitigation strategy
  • Identifies key experiments mitigating the risk of clinical failure
  • Integrates clinical and non-clinical requirements to speed up drug development
  • Anticipates and considers regulatory needs for successful milestone coverage

Thomas Christoph, PhD

“I am fascinated by Translational Pharmacology, the interface between
non-clinical and clinical efficacy. I am convinced that human Target
Validation and continuous development of the 3R’s will increase the
Translational Value in Drug Development.”

Blog

10th BioRiver Boost! 2023

04.10.2023|

The 10th edition of BioRiver’s competition boosting young Startups into networking of the NRW biotech scene was held at the LifeHub Monheim on Sep 22, 2023.

Teaching is Fun

09.07.2021|

Students fascinated by Drug Development will pave the way for innovative treatments.

Painful Lessons Learned from QST

23.03.2021|

QST has been developed as standardized assessment of sensory functions and widely used to analyze chronic pain conditions. Which implications does the recently published “failure” of QST in neuropathic pain patients have for animal testing?